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background: We investigated the relationship between myocardial scar and clinical response to transendocardial transplantation of CD34+ stem 
cells in patients with chronic heart failure (CHF).
Methods: In a prospective study, we enrolled 64 CHF patients with NYHA class III heart failure and LVEF<40%. In all patients, peripheral blood 
CD34+ cells were mobilized by G-CSF and collected via apheresis. NOGA electroanatomical mapping was performed to define areas of scar (unipolar 
voltage <9 mV and linear shortening <6%) versus hibernating myocardium (unipolar voltage ≥9 mV and linear shortening <6%). CD34+ cells were 
injected transendocardially in the hibernating areas. Patient were followed for 3 months after the procedure; good responders were defined as 
patients with LVEF increase of ≥5%.
results: Of 64 patients enrolled, 33 (52%) were good responders (Group 1) and 31 (48%) were not (Group 2). The two groups did not differ 
with regards to age (53±9 years in Group 1 vs. 53±9 years in Group 2, P=0.78), gender (male: 79% vs. 81%, P=0.72), heart failure etiology 
(ischemic: 45% vs. 37%, P=0.10), baseline LVEF (28±8% vs. 30±7%, P=0.10), and NT-proBNP (1,846±2,486 pg/mL vs. 2,795±4,371 pg/mL, 
P=0.28). On electroanatomical mapping, scarred myocardium was present in 2.34±2.02 of 9 myocardial segments (26%). We found no significant 
correlation between clinical response at 3 months and myocardial scar burden (2.15±1.84 scar segments in Group 1 vs. 2.55±2.20 segments 
in Group 2, P=0.44). Similarly, there was no significant difference between the groups with regards to hibernation segments (1.36±1.25 in Group 
1 vs. 1.81±1.87 in Group 2, P=0.27) and hibernation/scar ratio (0.71±0.91 in Group 1 vs. 0.78±1.02 in Group 2, P=0.78). Furthermore, mean 
myocardial viability as measured by unipolar voltage was similar in both groups (8.76±2.76 mV in Group 1 vs. 8.14±2.18 mV in Group 2, P=0.32).
conclusions:  Myocardial scar burden on electroanatomical mapping does not appear to predict response to transendocardial CD34+ stem cell 
transplantation in patients with CHF.
